Thursday 16 October, 2025
Objectives: Monoclonal antibodies (mAb) targeting the programmed cell death (PD-1) pathway have shown anticancer activity in different tumor types, though…
Read morePoster: Drug/Disease Modelling - Oncology
The tumor time-course predicts the overall survival in non-small cell lung cancer patients treated with atezolizumab in a large Phase I study: an evaluation of using different censoring times
Thursday 16 October, 2025
Objectives: Atezolizumab (an immunooncology checkpoint inhibitor) was administered to 88 non-small cell lung cancer (NSCLC) patients in the phase I,…
Read moreApplication of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II study
Thursday 16 October, 2025
Introduction: Inactivation of tumor protein 53 (p53) is a key mechanism which promotes tumor survival and proliferation. p53 inactivation can be…
Read moreUsing mixed effects modelling improves detection of drug-gene interactions in mouse trials
Thursday 16 October, 2025
Objectives: Mouse trials use multiple patient derived xenografts (PDXs) in order to reflect the heterogeneity in clinical cancer trials and to…
Read moreThe purpose determines the predictive performance: Comparison of four population pharmacokinetic models of methotrexate.
Thursday 16 October, 2025
Objectives: High-dose methotrexate (HD-MTX) is a highly effective anticancer treatment in cancer patients. In order to support therapeutic drug monitoring…
Read moreDynamic in vitro PKPD assessment to improve pharmacological response profiling of T-cell bispecifics
Thursday 16 October, 2025
Objectives: The approach for First-in-Human dose selection for cancer immunotherapy is typically based on minimally-anticipated biological effect level (MABEL) using in…
Read moreMechanistic joint modelling for longitudinal PSA and survival data in advanced metastatic prostate cancer
Thursday 16 October, 2025
Objectives: In phase III clinical trials, treatments for metastatic Castration-Resistant Prostate Cancer (mCRPC) are evaluated on their impact on time-to-death….
Read morePopulation PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia
Thursday 16 October, 2025
Introduction: Asparaginase is an important agent in the treatment of acute lymphoblastic leukemia. PEG-L-asparaginase (Pegaspargase) is Escherichia coli L-asparaginase (L-ASP)…
Read moreMechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer
Thursday 16 October, 2025
Objectives: Build a mechanistic multi scale model for gemcitabine based on its molecular metabolic pathway, integrating in vitro- in vivo…
Read morePKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma
Thursday 16 October, 2025
Objectives: This work evaluates the PK-PD relationships of a NCE aimed at the inhibition of oncogene amplification through in vitro…
Read more